Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2025-08-03
Target enrollment:
Participant gender:
Summary
This research study is evaluating a new type of personalized neoantigen cancer
vaccine（iNeo-Vac-P01）combined with anti-PD-1 antibody and radiofrequency ablation as a
possible treatment for patients with advanced solid tumors. The primary objective of this
trial is to evaluate safety, tolerability and immunogenicity of iNeo-Vac-P01 in combination
with anti-PD-1 and radiofrequency ablation, so as to provide a new personalized therapeutic
strategy for patients.
It is known that cancer patients have mutations (changes in genetic material) that are
specific to an individual patient and tumor. These mutations can cause the tumor cells to
produce proteins that appear very different from the body's own cells. It is possible that
these proteins used in a vaccine may induce strong immune responses, which may help the
participant's body fight any tumor cells that could cause the cancer to come back in the
future. The study will examine the safety of the vaccine when given at several different time
points and will examine the participant's blood cells for signs that the vaccine induced an
immune response.